Compare BioNano Genomics Inc (BNGO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs GeneDx Holdings Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while GeneDx Holdings Corp trades at $63.17 (market cap $1.85B). The key difference: GeneDx Holdings Corp is far larger — about 140.2× BioNano Genomics Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | WGS | |
|---|---|---|
Market Cap | $13.20M | $1.85B |
Sector | Health | Technology |
52-Week High | $4.92 | $167.51 |
52-Week Low | $1.09 | $34.51 |
Enterprise Value | $15.81M | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
